Results 141 to 150 of about 308,545 (256)

Improvement in Activities of Daily Living Among Older Adults With Physician-Led Home Visits: A Multicenter Retrospective Cohort Study in Japan. [PDF]

J Gen Fam Med
Hinata Y, Matsushima M, Aoki T, Sugiyama Y, Kanno T, Fujinuma Y, Watanabe T.   +6 more
europepmc   +1 more source

PrEP at the site of action in cisgender and transgender women: A pharmacology study of blood and rectal CD4+ lymphocytes

British Journal of Clinical Pharmacology, EarlyView.
Background Female sex hormones used in feminizing hormone therapy (FHT) may influence activation and persistence of HIV pre‐exposure prophylaxis (PrEP) medications. The clinical relevance of this interaction remains unclear, particularly for transgender and cisgender women (TGW and CGW).
Elizabeth Hastie, Megha Srivasta, Edward R. Cachay, Leah Burke, Sara Gianella, Stephen Rawlings, Frank Z. Stanczyk, Craig Sykes, Angela D. M. Kashuba, Jill Blumenthal, Mackenzie L. Cottrell   +10 more
wiley   +1 more source

A community programme of home visits by dieticians after discharge from geriatric acute care wards: baseline characteristics according to weight change during follow-up. [PDF]

BMC Geriatr
Sanchez M, Courtois-Amiot P, Götze K, Lazzari S, Roux S, Jallot B, Paris E, Chansiaux-Buccalo C, Raynaud-Simon A.   +8 more
europepmc   +1 more source

Evaluating a virtual paediatric adverse drug reaction clinic

British Journal of Clinical Pharmacology, EarlyView.
Aims Adverse drug reactions (ADRs) are a common problem in paediatric health care. There is limited access to expertise in the evaluation and management of potential ADRs in children, limiting access to these services and creating delays in assessment and management.
Emily Hauck, Blanca Del Pozzo‐Magana, Michael Rieder   +2 more
wiley   +1 more source

Parental experiences from home visits in the New Families programme: an observational and interview study. [PDF]

BMC Nurs
Holmberg Fagerlund B, Glavin K.
europepmc   +1 more source

S. aureus colonization and clinical symptoms remain stable upon topical XZ.700 treatment: Results of a double‐blind randomized clinical trial in patients with mild to moderate atopic dermatitis

British Journal of Clinical Pharmacology, EarlyView.
Aim Recovering dysbiosis may improve atopic dermatitis (AD) symptoms. XZ.700 is a recombinant chimeric endolysin that specifically targets Staphylococcus aureus and could be a new treatment option for patients with AD. The aim of this first‐in‐human study was to evaluate the safety, tolerability and efficacy of topical XZ.700 and explore the ...
Laura W. J. van der Meulen, Menthe E. Bergmans, Salma Assil, Naomi Klarenbeek, Marieke L. de Kam, Alexa J. Tibboel, Thorsten Brach, Bjorn L. Herpers, Johan Frieling, Vincent de Jong, Benthe Freyee, Martijn B. A. van Doorn, Robert Rissmann, Tessa Niemeyer–van der Kolk   +13 more
wiley   +1 more source

Health‐related quality of life following total minimally invasive, hybrid minimally invasive or open oesophagectomy: a population‐based cohort study

BJS (British Journal of Surgery), EarlyView., 2020
All patients operated for oesophageal cancer in Sweden from 2013 to April 2018 were identified, and 246 patients were recruited to this population‐based nationwide Swedish study. The results show that longitudinal health‐related quality of life after minimally invasive oesophagectomy was similar to that of the open surgical approach.
F. Klevebro, J. H. Kauppila, S. Markar, A. Johar, P. Lagergren   +4 more
wiley   +1 more source

Home visits [PDF]

Canadian Medical Association Journal, 2010
openaire   +1 more source

A qualitative assessment of older adults' perspective on the utilization of information from preventive home visits. [PDF]

Aging Clin Exp Res
Nivestam A, Edfors E, Hedin G, Westergren A, Haak M.   +4 more
europepmc   +1 more source

Exploring individualized crovalimab dosing in PNH through in silico modelling: Potential for improved convenience and cost efficiency

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aim Paroxysmal nocturnal haemoglobinuria (PNH) is a rare, acquired haematopoietic stem cell disorder. Crovalimab, a complement C5‐inhibitor, is approved for PNH and can be self‐administered subcutaneously every 4 weeks, offering a more convenient route than intravenous C5‐inhibitors.
Mendy ter Avest, Simon E. Koele, Nicole C. A. J. van de Kar, Saskia M. C. Langemeijer, Rob ter Heine   +4 more
wiley   +1 more source